Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ: COAG · Real-Time Price · USD
24.98
-1.96 (-7.28%)
Jun 12, 2026, 4:00 PM EDT - Market closed

COAG Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024
Period Ending
Dec '25 Dec '24
Selling, General & Admin
10.498.97
Research & Development
59.6341.41
Total Operating Expenses
70.1250.38
Operating Income
-70.12-50.38
Interest Income
1.973.74
Other Non-Operating Income (Expense)
4.01-1.88
Total Non-Operating Income (Expense)
5.981.86
Pretax Income
-64.14-48.52
Provision for Income Taxes
-0.230.19
Net Income
-63.91-48.71
Net Income to Common
-63.91-48.71
Shares Outstanding (Basic)
11
Shares Outstanding (Diluted)
11
EPS (Basic)
-67.56-51.49
EPS (Diluted)
-67.56-51.49
EBIT
-70.12-50.38
SEC Filings: 10-K · 10-Q